Alzheimer's disease: progress to be confirmed

This article is from the magazine Les Dossiers de Sciences et Avenir n°223 dated October/December 2025.

A major disappointment for Alzheimer's patients and the associations that support them. On September 9th, the French National Authority for Health (HAS) refused to grant emergency approval for the reimbursement of Leqembi, which entered the European market in April. A second treatment aimed at eradicating amyloid plaques – one of the causes of Alzheimer's disease – could, however, be marketed this year. This is Kisunla (donanemab), which received approval from the European Medicines Agency in July. Both are monoclonal antibodies, custom-made drugs produced from immune cells grown in the laboratory.